Oppenheimer is out with its report today on Prestige Brands PBH, maintaining Perform.
In its report, Oppenheimer writes, "We continue to be impressed by PBH's transformation under CEO Matt Mannelly, with an improved portfolio, solid growth among its core OTC brands and likely M&A opportunities. That said, we are maintaining our Perform rating on the shares, as we believe headwinds such as the future return of Children's Tylenol to store
shelves and meaningful increases in A&P spending could cause near-term volatility, although long-term investors should consider the name on dips."
Shares of PBH closed Wednesday at $9.82, up 1.34% from Tuesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in